Patients who experience a warfarin-associated gastrointestinal tract bleeding event should resume anticoagulation therapy during the 90 days following the event to decrease the risk of thrombosis and death, according to a study published online in the Archives of Internal Medicine.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Resuming warfarin after GIB event decreases risk of thrombosis, death

Newsletter